Why the study?
What demographic, clinical, and genetic factors are associated with clopidogrel resistance in subjects receiving clopidogrel?
What demographic, clinical, and genetic factors are associated with clopidogrel resistance in subjects receiving clopidogrel?
Clinical and demographic factors such as female sex, advanced age, obesity, and higher platelet count, but not specific genetic polymorphisms, are associated with clopidogrel resistance.
Answers are grounded in this paper and cite their sources.
Clinical factors may flag clopidogrel resistance risk; leaves open whether these genetic polymorphisms meaningfully contribute.
Clopidogrel is an antiplatelet agent that is indicated for cardiovascular emergencies and procedures. The drug, however, is subject to response variability leading to therapy resistance. In this research, we explored the demographic, clinical, and genetic factors associated with clopidogrel resistance. Data analysis among our 280 subjects receiving clopidogrel showed some risk factors that are significantly associated with clopidogrel resistance compared with responders. Those were: female sex (P = 0.021), advanced age (P = 0.011), obesity (P = 0.002), and higher body mass index (P = 0.008) and higher platelets count (P = 0.002). However, known polymorphisms of MDR-1, CYP1A2, CYP3A4, and CYP3A5 were not associated with treatment resistance when compared to responders to clopidogrel therapy. Knowledge about such risk factors might provide recommendation in the future about starting doses or monitoring recommendations.
No takes yet. Share an insight, caveat, or question.
Al‐Husein et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: